This technology includes a series of imidazo[1,2-a]pyridines that potently inhibit FLT3, which can be utilized as an anticancer agent. These molecules retain potent binding and activity against FLT3 tyrosine kinase domain and gatekeeper mutations. This chemotype exhibits superior anti-leukemic activity against clinically-relevant FLT3-mutant acute myeloid leukemia (AML) in vitro and in vivo. Tyrosine kinase domain mutations are a common cause of acquired resistance to FLT3 inhibitors used to treat FLT3-mutant AML.
Used to treat a variety of hematological diseases, including but not limited to AML, myeloid dysplastic syndrome, Diffuse Large B-cell Lymphoma, and other blood cancers.
These agents have activity versus mutations in the acquired resistance space and versus non-IRAK inhibitors in the adaptive resistance space.